Stummer, Walter5; Rodrigues, Floriano6; Schucht, Philippe6; Preuss, Matthias6; Wiewrodt, Dorothee6; Nestler, Ulf6; Stein, Marco6; Artero, José Manuel Cabezudo6; Platania, Nunzio6; Skjøth-Rasmussen, Jane6; Della Puppa, Alessandro6; Caird, John6; Cortnum, Søren4; Eljamel, Sam6; Ewald, Christian6; González-García, Laura6; Martin, Andrew J6; Melada, Ante6; Peraud, Aurelia6; Brentrup, Angela6; Santarius, Thomas6; Steiner, Hans Herbert6
1 Aalborg University Hospital, The Faculty of Medicine, Aalborg University, VBN2 Klinik Hoved-Orto, The Faculty of Medicine, Aalborg University, VBN3 Neurokirurgi, The Faculty of Medicine, Aalborg University, VBN4 The Faculty of Medicine, Aalborg University, VBN5 Department of Neurosurgery, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany, email@example.com unknown
a European survey
BACKGROUND: Five-aminolevulinic acid (Gliolan, medac, Wedel, Germany, 5-ALA) is approved for fluorescence-guided resections of adult malignant gliomas. Case reports indicate that 5-ALA can be used for children, yet no prospective study has been conducted as of yet. As a basis for a study, we conducted a survey among certified European Gliolan users to collect data on their experiences with children. METHODS: Information on patient characteristics, MRI characteristics of tumors, histology, fluorescence qualities, and outcomes were requested. Surgeons were further asked to indicate whether fluorescence was "useful", i.e., leading to changes in surgical strategy or identification of residual tumor. Recursive partitioning analysis (RPA) was used for defining cohorts with high or low likelihoods for useful fluorescence. RESULTS: Data on 78 patients <18 years of age were submitted by 20 centers. Fluorescence was found useful in 12 of 14 glioblastomas (85 %), four of five anaplastic astrocytomas (60 %), and eight of ten ependymomas grades II and III (80 %). Fluorescence was found inconsistently useful in PNETs (three of seven; 43 %), gangliogliomas (two of five; 40 %), medulloblastomas (two of eight, 25 %) and pilocytic astrocytomas (two of 13; 15 %). RPA of pre-operative factors showed tumors with supratentorial location, strong contrast enhancement and first operation to have a likelihood of useful fluorescence of 64.3 %, as opposed to infratentorial tumors with first surgery (23.1 %). CONCLUSIONS: Our survey demonstrates 5-ALA as being used in pediatric brain tumors. 5-ALA may be especially useful for contrast-enhancing supratentorial tumors. These data indicate controlled studies to be necessary and also provide a basis for planning such a study.
Acta Neurochirurgica, 2014, Vol 156, Issue 12, p. 2315-2324